Stockscreener 앱 받기
8.10
32.35%
1.98
시간 외 거래:
8.05
-0.05
-0.62%
전일 마감가:
$6.12
열려 있는:
$6.08
하루 거래량:
93,523
Relative Volume:
1.00
시가총액:
$13.39M
수익:
$368.00K
순이익/손실:
$-9.54M
주가수익비율:
-16.92
EPS:
-0.4788
순현금흐름:
$-9.47M
1주 성능:
+51.69%
1개월 성능:
+1,262%
6개월 성능:
+1,201%
1년 성능:
+875.90%
1일 변동 폭
$5.95
$8.26
1주일 범위
$5.27
$8.26
52주 변동 폭
$0.35
$8.26
Lexaria Bioscience Corp Stock (LEXX) Company Profile
명칭
Lexaria Bioscience Corp
전화
250-765-6424
주소
100 - 740 MCCURDY ROAD, KELOWNA
Compare LEXX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LEXX
Lexaria Bioscience Corp
|
8.10 | 10.11M | 368.00K | -9.54M | -9.47M | -0.4788 |
VRTX
Vertex Pharmaceuticals Inc
|
516.44 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.97 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
856.94 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
202.00 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
356.01 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lexaria Bioscience Corp 주식(LEXX)의 최신 뉴스
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know - Benzinga
Lexaria Signs PegBio Deal to Test DehydraTECH With GLP-1 Diabetes Drug - TipRanks
Lexaria enters partnership with PegBio for GLP-1 drug delivery - Investing.com
Lexaria Enters a Material Transfer Agreement With PegBio - Investing News Network
Lexaria enters partnership with PegBio for GLP-1 drug delivery By Investing.com - Investing.com India
News by ACCESS Newswire on TradingView, 2026-08-13 - TradingView
Lexaria Bioscience Received Notice of Delisting - TradingView
Lexaria Bioscience Stock Price Forecast. Should You Buy LEXX? - StockInvest.us
Lexaria Bioscience Corp (LEXX) Stock News Today - TradingKey
Lexaria Bioscience Corp (LEXX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Corp Authorizes 1-For-15 Reverse Stock SplitSEC Filing - TradingView
Lexaria Bioscience plans 1-for-15 reverse stock split By Investing.com - Investing.com Nigeria
Lexaria Bioscience Corp. Revenue Breakdown – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lexaria Bioscience Corp (LEXX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lexaria Bioscience Corp (LEXX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LEXX|Lexaria Bioscience Corp|Price:0.559|Chg%:-0.011 - TradingKey
Enterprise value to revenue forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp (LEXX) Cash Flow - TradingKey
Lexaria Bioscience Corp (LEXX) Income Statement - TradingKey
LEXX|Lexaria Bioscience Corp|Price:5.390|Chg%:+0.120 - TradingKey
Lexaria Bioscience Corp (LEXX) Earnings Date & Reports & Earnings News - TradingKey
Lexaria Bioscience Corp (LEXX) Institutional Confidence - TradingKey
Price to book forward of Lexaria Bioscience Corp. – NASDAQ:LEXX - TradingView
Lexaria Bioscience Corp. 10-Q Q3 2026: Financial Results, NASDAQ Listing, and Key Highlights - Minichart
Lexaria Bioscience narrows Q3 loss to $(0.08) per share - scanx.trade
LEXARIA BIOSCIENCE ($LEXX) Releases Q3 2026 Earnings - Quiver Quantitative
Lexaria Bioscience Corp. 2026: Revenue $0 EPS ($0.08) — 10-Q Summary - TradingView
Lexaria Bioscience (NASDAQ: LEXX) narrows loss but warns on cash and Nasdaq bid - Stock Titan
Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026 - marketscreener.com
Lexaria Bioscience Corp expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Lexaria reports pharmaceutical partnership discussions at BIO - Investing.com
Lexaria reports pharmaceutical partnership discussions at BIO By Investing.com - Investing.com Nigeria
Lexaria Updates Business Development - Investing News Network
Lexaria pitches DehydraTECH to drugmakers at BIO as GLP-1 safety focus grows - Stock Titan
LEXXLexaria Bioscience Corp Forecast, Target Price - Finviz
Lexaria Bioscience Corp. Actuals & Estimates (NASDAQ:LEXX) - TradingView
Lexaria Begins Dosing in Human Study Evaluating Oral Semaglutide Formulations Against Wegovy - citybuzz -
Lexaria's Human Study GLP-1-H26-7 Has Begun Dosing on Schedule - Investing News Network
Lexaria starts 5-week human GLP-1 study using tablet and capsule forms - Stock Titan
Lexaria Bioscience (LEXX) Advances in Animal Study #1 on Formula - GuruFocus
Lexaria's Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule - Investing News Network
Lexaria starts animal GLP-1 study, adds Australian patent - Stock Titan
Lexaria Bioscience Corp (LEXXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lexaria Bioscience Corp (LEXXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lexaria Bioscience Corp. Financial Disclosures & SEC Filings - TradingView
Lexaria Bioscience Corp (LEXXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lexaria Bioscience Corp (LEXXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexaria Bioscience Corp (LEXXW) Institutional Confidence - TradingKey
Lexaria Bioscience Corp (LEXX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lexaria Bioscience Corp (LEXXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Lexaria Bioscience Corp (LEXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.03%
0.33%
자본화:
|
볼륨(24시간):